¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Failure in dosage in electroshock or insulin-shock therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® heart failure ÇÑ±Û ½ÉÀå±â´É»ó½Ç
¼³¸í   
  ¸öÀÇ Á¶Á÷À̳ª ±â°ü¿¡¼­ ´ë»ç¿¡ ÇÊ¿äÇÑ ¸¸Å­ ÃæºÐÇÑ ¾çÀÇ Ç÷¾×À» °ø±ÞÇÒ ¼ö ¾øÀ» Á¤µµ·Î ½ÉÀå±â´ÉÀÌ ÀúÇϵǾî Àִ »óÅÂÀÌ´Ù. ½ÉÀå±â´É»ó½ÇÀº ½É±ÙÀÌ ¼öÃàÇÒ ´É·ÂÀÌ ÀúÇϵǾúÀ» ¶§³ª ½ÉÀå¿¡ ½É¹ÚÃâÀ» Çϱâ À§ÇÑ ¾Ð·ÂÀÌ Á¤»óº¸´Ù Áõ°¡µÇ¾î Á¤»óÀÇ ½ÉÀåÀÇ ¼öÃàÀ¸·Î´Â ÃæºÐÇÑ ¾çÀÇ Ç÷¾×À» °ø±ÞÇÒ ¼ö ¾ø´Â °æ¿ì, ±×¸®°í ½ÉÀå±ÙÀ°, ½ÉÀå¿¡ °É¸®´Â ¾Ð·ÂÀº Á¤»óÀ̳ª ½ÉÀå¹Úµ¿ÀÇ À̻󿡠ÀÇÇØ¼­ Á¤»óÀûÀΠ¼öÃàÀÌ ºÒ°¡´ÉÇÒ °æ¿ì¿¡ »ý±ä´Ù.
¿µ¹® congestive heart failure ÇÑ±Û ¿ïÇ÷¼º½ÉÀå±â´É»ó½Ç
¼³¸í   
  ½ÉÀåÀÇ ¿ø·¡ ±â´É, Áï Ç÷¾×À» ¸»ÃʷΠº¸³»´Â ÆßÇÁ¿Í °°Àº ±â´ÉÀÌ °ÅÀÇ ¾ø¾îÁø »óŸ¦ ¸»ÇÑ´Ù. ÇǸ¦ º¸³»´Â ÆßÇÁÀÇ ¿ªÇÒÀÌ ¸ØÃß¾úÀ¸¹Ç·Î ½ÉÀåÀ¸·Î µé¾î¿À´Â ÇǴ ½ÉÀåÀ¸·Î µé¾î¿ÀÁö ¸øÇϰí Á¤¸Æ¼Ó¿¡¼­ Á¤Ã¼ÇϰԠµÈ´Ù. ±×¸®ÇÏ¿© Ç÷¾×ÀÇ ´ëºÎºÐÀÌ ¸»ÃÊÀÇ Á¤¸Æ¿¡ ¸Ó¹°°Ô µÇ¾î ¿©·¯ °¡Áö Áõ»óÀÌ ³ªÅ¸³­´Ù. Æ¯È÷ ÇãÆÄ¸¦ µ¹¾Æ Á½ɹæÀ¸·Î µé¾î°¡¾ßÇϴ Çǰ¡ ÆßÇÁ ±â´ÉÀÌ ¾ø¾îÁ®¼­ ¿Þ½É¹æ¿¡ ¸¹Àº Çǰ¡ Á¤Ã¼Çϰí À־ µé¾î°¡Áö ¸øÇؼ­ ÇãÆÄ¿¡ °íÀ̰ԠµÈ´Ù. ±×·¯¸é ÇãÆÄ¿¡ »ê¼Ò¿Í ÀÌ»êȭź¼Ò¸¦ ±³È¯Çϴ ±â´ÉÀÌ ¾ø¾îÁ®¼­ ¼ûÀ» ½¬Áö ¸øÇϴ °á°ú¸¦ ³½´Ù. Áï ¼ûÀÌ Â÷°í ¼û½¬±â Èûµç Áõ¼¼°¡ ³ªÅ¸³­´Ù. ¶Ç ¿Â¸öÀ» ¼øÈ¯ÇÑ ´ÙÀ½¿¡ ¿ì½É¹æÀ¸·Î µé¾î¿Í¾ßÇϴ Çǵµ ¿ì½É¹æÀ¸·Î µé¾î¿ÀÁö ¸øÇؼ­ ¸»ÃÊ¿¡ Á¤Ã¼ÇϹǷΠ¿Â¸öÀÌ º×°Ô µÈ´Ù.
¿µ¹® family therapy ÇÑ±Û °¡Á·¿ä¹ý
¼³¸í   
  °¡Á·À» Ä¡·á ´ë»óÀ¸·Î Çϴ ½É¸®¿ä¹ý ÁßÀÇ Çϳª. °¡Á·ÁßÀÇ ¹®Á¦´Â ¹®Á¦¸¦ °¡Áø °³Àθ¸ÀÌ ¾Æ´Ï¶ó ¹®Á¦ °¡Á·À» ´ë»óÀ¸·Î ÇذáÇØ ³ª°¥ Çʿ䰡 Àִٴ ÀνÄÀ» ¹ÙÅÁÀ¸·Î ÇÏ¿© °¡Á· ÀüüÀÇ ½É¸®Àû ¼º¼÷À» ¸ñÇ¥·Î ÇÑ ¿ä¹ýÀÌ´Ù. Å©°Ô ³ª´©¾î °¡Á· ÁßÀǠƯÁ¤ÀÎÀ» ´ë»óÀ¸·Î ÇÏ¿© °¢°¢ ´Ù¸¥ µ¶¸³µÈ Ä¡·á¸¦ Çϴ º´Çà½É¸®¿ä¹ý°ú °¡Á· Àüü¸¦ µ¿½Ã ¸éÁ¢Çϴ ¹æ¹ýÀ» ÁַΠÇϴ ÇÕµ¿°¡Á·¿ä¹ýÀÌ Àִµ¥, Æ¯È÷ ÈÄÀÚ¸¦ °¡¸®ÄÑ °¡Á·¿ä¹ý À̶ó°í Çϴ °æ¿ì°¡ ¸¹´Ù.
¿µ¹® intracavitary therapy ÇÑ±Û °­³»¿ä¹ý
¼³¸í   
  Ã¼°­³», Áï ÀÔ¾È, ÄÚ¾È, Àεΰ­, ½Äµµ, °ðâÀÚ, Áú, Àڱøñ, ¹æ±¤ µîÀÇ ³»°­¿¡, ¶§·Î´Â º´ÅÍ¿¡ ÀÇÇØ »ý±ä °øµ¿³»¿¡ ¹æ»ç¼±À» »ðÀÔÇØ¼­ Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. ÁַΠÁ¾¾çÀÇ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ´Ù.
¿µ¹® hyperbaric oxygenation therapy ÇÑ±Û °í¾Ð»ê¼Ò¿ä¹ý
¼³¸í   
  ´ë±â¾Ðº¸´Ù ³ôÀº ±â¾Ðȯ°æÀ» ÀΰøÀûÀ¸·Î ¸¸µé¾î ±× ¾È¿¡¼­ °í³óµµÀÇ »ê¼Ò¸¦ ÈíÀÔ½Ã۴ ¿ä¹ý. Çѱ¹¿¡¼­ ¿¬Åº°¡½º·Î ´ëÇ¥µÇ´Â ÀÏ»êȭź¼ÒÀÇ ±Þ¼ºÁßµ¶ÀÇ Ä¡·á¿¡ ¸¹ÀÌ ÀÌ¿ëµÈ °ÍÀ¸·Î, º¸Åë 3´ë±â¾Ð Á¤µµ·Î °¡¾ÐµÈ °í¾Ð»ê¼Ò½ÇÀ̳ª °í¾Ð»ê¼ÒÅÊÅ© ¼Ó¿¡ È¯ÀÚ¸¦ ³õ°í Àü½Å¿¡ »ê¼Ò¸¦ ÈíÀÔ½ÃŲ´Ù. °í¾Ð½ÇÀº Å©°í ÀÛÀº ¿©·¯ °¡Áö°¡ ÀÖÀ¸¸ç, ±¸Á¶»ó 1½Ç½Ä-2½Ç½Ä-´Ù½Ç½ÄÀÌ ÀÖ´Ù. °¡¾Ð °¡½ºÀÇ Á¾·ù¿¡´Â »ê¼Ò-°ø±â-È¥ÇÕ °¡½ºµîÀÌ ÀÖ°í, 2~3 ´ë±â¾Ð ¶Ç´Â ±× ÀÌ»óÀÇ °í¾Ð È¯°æÀ» ¸¸µç´Ù. ÀÓ»óÀûÀ¸·Î ÀÀ¿ë¹üÀ§°¡ ³Ð¾î¼­ ±â°èÀû È¿°ú¿¡ ÀÇÇÏ¿© Àá¼öºÎº´À̳ª Ã¢ÀÚ°ü¸¶ºñ¿¡ ÀÇÇѠâÀÚÆó»ö Ä¡·á µî¿¡ À¯È¿Çϰí, °¡½º±ËÀú µîÀÇ ¹«»ê¼Ò¼º ¼¼±Õ°¨¿°¿¡¼­µµ ÀÌ¿ëµÈ´Ù. ¶Ç »ê¼Ò¿î¹ÝÈ¿°ú¿¡ ÀÇÇÏ¿© ÀÏ»êȭź¼Ò-½É±Ù°æ»ö-³ú»öÀüÁõ-ÃâÇ÷¼îÅ©¿¡ ÀÇÇÑ ±Þ¼ºÀÇ Á¶Á÷»ê¼Ò°áÇÌÀÇ Ä¡·á¿¡ À¯È¿ÇÏ´Ù. ¶Ç ¾ÏÀÇ ¹æ»ç¼±¿ä¹ý¿¡ º´¿ëÇϸé ÀÌ ¿ä¹ýÀ¸·Î ¾Ï¼¼Æ÷ÀÇ ºÐ¿­ÀÌ ¿Õ¼ºÇØÁ®, ¼¼Æ÷ºÐ¿­ ÁßÀΠ¼¼Æ÷¿¡ ¹æ»ç¼±À» Á¶»çÇÔÀ¸·Î½á ºÐ¿­´É·ÂÀ» ¾ø¾Ö´Â µ¥ À¯È¿ÇÏ¿© °í¾Ð»ê¼ÒÈíÀÔÁ¶»ç¹ýÀ̶ó°í ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • electroshock
    Àü±âÃæ°Ý
  • adult dosage
    ¼ºÀο뷮
  • dosage
    1. ¿ë·®, Åõ¿©·® 2. ¼±·®, Á¶»ç·®
  • gene dosage compensation
    À¯ÀüÀÚ¿ë·®º¸»ó
  • initial dosage
    ÃÖÃÊÅõ¿©·®
  • pediatric dosage
    ¼Ò¾Æ¿ë·®
  • stabilization dosage
    ¾ÈÁ¤È­·®
  • atrial failure
    ½É¹æ±â´É»ó½Ç, ½É¹æºÎÀü
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü
  • backward heart failure
    µÚÂʽÉÀå±â´É»ó½Ç, ÈÄÇâ½É(Àå)ºÎÀü
  • circulatory failure
    ¼øÈ¯±â´É»ó½Ç, ¼øÈ¯ºÎÀü
  • congestive heart failure
    ¿ïÇ÷½ÉÀå±â´É»ó½Ç, ¿ïÇ÷½ÉºÎÀü
  • cardiac failure
    ½ÉÀå±â´É»ó½Ç, ½É(Àå)ºÎÀü
  • chronic renal failure
    ¸¸¼ºÄáÆÏ±â´É»ó½Ç, ¸¸¼º½ÅºÎÀü
  • failure
    ±â´É»ó½Ç, ºÎÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • electroshock
    Àü±âÃæ°Ý
  • failure
    ±â´É»ó½Ç
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü(Áõ)
  • chronic renal failure
    ¸¸¼ºÄáÆÏ±â´É»ó½Ç, ¸¸¼º½ÅºÎÀü(Áõ)
  • fulminant hepatic failure
    Àü°Ý°£±â´É»ó½Ç, Àü°Ý°£ºÎÀü
  • hemostatic failure
    ÁöÇ÷±â´É»ó½Ç, ÁöÇ÷ºÎÀü
  • ovarian failure
    ³­¼Ò±â´É»ó½Ç, ³­¼ÒºÎÀü
  • respiratory failure
    È£Èí±â´É»ó½Ç, È£ÈíºÎÀü
  • therapy
    ¿ä¹ý
  • acetylsalycylic acid antiplatelet therapy
    Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • antibiotic therapy
    Ç×»ýÁ¦¿ä¹ý
  • ASA antiplatelet therapy
    (¢¡acetylsalycylic acid antiplatelet therapy) Ç×Ç÷¼ÒÆÇ¿ä¹ý
  • behavioral therapy
    Çൿ¿ä¹ý
  • electroconvulsive therapy
    Àü±â°æ·Ã¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • electroshock
    Àü±âÃæ°Ý
  • adult dosage
    ¼ºÀο뷮
  • dosage
    ¿ë·®, Åõ¿©·®
  • initial dosage
    ÃÖÃÊÅõ¿©·®
  • stabilization dosage
    ¾ÈÁ¤·®
  • atrial failure
    ½É¹æ±â´É»ó½Ç
  • backward failure theory
    ÈĹæÀå¾Ö¼³
  • backward heart failure
    µÚÂʽÉÀå±â´É»ó½Ç, ÈÄÇâ½ÉÀåºÎÀü
  • cardiac failure
    (¢¡heart failure) ½ÉÀå±â´É»ó½Ç, ½ÉÀåºÎÀü
  • circulatory failure
    ¼øÈ¯±â´É»ó½Ç, ¼øÈ¯ºÎÀü
  • congestive heart failure
    ¿ïÇ÷½ÉÀå±â´É»ó½Ç, ¿ïÇ÷½ÉºÎÀüÁõ
  • failure
    ±â´É»ó½Ç
  • forward heart failure
    ¾ÕÂʽÉÀå±â´É»ó½Ç, Àü¹æ½ÉÀåºÎÀü
  • heart failure
    ½ÉÀå±â´É»ó½Ç, ½ÉÀåºÎÀü
  • high-output heart failure
    °í¹ÚÃâ½ÉÀå±â´É»ó½Ç, °í¹ÚÃâ½ÉÀåºÎÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • EST See Electroshock therapy
    Àü±âÃæ°Ý¿ä¹ý(ï³Ñ¨õú̪èþÛö)
  • adult dosage
    ¼ºÀη®(¡­åÖ).
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • initial dosage
    ÃÖÃÊÅõ¿©·®.
  • radiation dosage
    ¹æ»ç¼±·®
  • Congestive heart failure
    ¿ïÇ÷¼º(ê¦úìàõ)½ÉºÎÀü(ãýÜôîï)
  • Heart failure
    ½ÉºÎÀü(ãýÜôîï)
  • RFI=>renal failure index
    ½ÅºÎÀüÁö¼ö
  • acute heart failure
    ±Þ¼º ½ÉºÎÀü(¡­ãýÝÕîï).
  • acute renal failure
    ±Þ¼º ½ÅºÎÀü(Áõ)(¡­ãìÝÕîïñø).
  • fusion failure
    À¶ÇÕºÎÀü
  • growth failure
    ¼ºÀåºÎÀü(à÷íþÝÕîï).
  • heart failure
    ½ÉºÎÀü(ãýÝÕîï).
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • hepatic failure
    °£ºÎÀü(ÊÜÝÕîï).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • electroshock
    Àü±â¼ï.
  • electroshock
    Àü±âÃæ°Ý
  • electroshock treatment
    Àü±âÃæ°ÝÄ¡·á
  • cardiac failure =heart failure
    ½ÉºÎÀü(Áõ)(ãýÜôîï[ñø]).
  • cardiac failure =heart failure
    ½ÉºÎÀü(Áõ)(ãýÝÕîïñø).
  • adult dosage
    ¼ºÀη®(¡­åÖ).
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • dosage/dose
    »ç¿ë·®, Åõ¿©·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • initial dosage
    ÃÖÃÊÅõ¿©·®.
  • radiation dosage
    ¹æ»ç¼±·®
  • spironolactone dosage
  • stabilization dosage
    ¾ÈÁ¤·®(äÌïÒåÖ).
  • usual dosage =u. dose
    »ó¿ë·®(ßÈéÄåÖ).
  • acute heart failure
    ±Þ¼º ½ÉºÎÀü(¡­ãýÝÕîï).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • malarial therapy
    ¸»¶ó¸®¾Æ¿ä¹ý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gene dosage
    À¯ÀüÀÚ ·®(ë¶îîí­Õá)
  • antidotal therapy
    Ç×ÇØµ¶Ä¡·á(ù÷ú°Ô¸ö½Öû)
  • enzyme replacement therapy
    È¿¼Ò ´ëü Ä¡·á (ý£áÈÓÛôðö½Öû)
  • enzyme therapy
    È¿¼ÒÄ¡·á (ý£áÈö½Öû)
  • gene therapy
    À¯ÀüÀÚ Ä¡·á(ë¶îîí­ö½Öû)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • dosage
    ¿ë·®
  • radiation dosage
    ¹æ»ç¼±·®
  • cardiac failure
    ½ÉºÎÀüÁõ
  • failure
    ºÎÀüÁõ, ÆÄ¼Õ
  • heart failure
    ½ÉºÎÀü
  • hepatic failure
    °£ºÎÀü
  • high output heart failure
    °í¹ÚÃ⼺½ÉºÎÀü
  • renal failure
    ½ÅºÎÀü
  • respiratory failure
    È£ÈíºÎÀü
  • adjuvant therapy
    º¸Á¶¿ä¹ý
  • isotope therapy
    µ¿À§¿ø¼ÒÄ¡·á
  • maintenance therapy
    À¯Áö¿ë¹ý
  • percutaneous ethanol injection therapy
    °æÇÇÀû¿¡Å¸³îÁÖÀÔ¿ä¹ý
  • radiation therapy
    ¹æ»ç¼±Ä¡·á
  • radium therapy
    ¶óµãÄ¡·á
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MES maintenance electrolyte solution; maximal electroshock; maximal electroshock seizures; myoelectric s...
POF pattern of failure; position of function; premature ovarian failure; primary ovarian failure; pyruva...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
IT immunological test; immunotherapy; implantation test; individual therapy; information technology; in...
MT magnetization transfer; malaria therapy; malignant teratoma; mammary tumor; mammilothalamic tract; m...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
MTD Maximum tolerated dosage
MES Maximal Electroshock
M.E.S. Maximal Electroshock Seizure
MES maximal electroshock-induced seizure
ARF Acute Renal Failure
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • Y63.4
    Failure in dosage in electroshock or insulin-shock therapy
    Àü±âÃæ°Ý ¶Ç´Â Àν¶¸°¼îÅ© Ä¡·á¿¡¼­ ¿ë·® ½Ç¼ö
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electroshock
    Àü±â ¼ï
    ³ú¿¡ ÅëÀüÇÏ¿© ¼îÅ©¸¦ ÀÏÀ¸Å°´Â °Í.
  • adult dosage
    ¼ºÀη®
  • dosage
    ¿ë·®, ¿ë·® °áÁ¤, °è·®
    ¾àÀÇ Å©±â¿Í Ƚ¼ö, °¹¼öÀÇ °áÁ¤°ú Á¶Àý.
  • dosage rate
    ¼±·®·ü, ¿ë·®
  • stabilization dosage
    ¾ÈÁ¤·®
  • acute heart failure
    ±Þ¼º ½ÉºÎÀü
    ±Þ¼º ¼øÈ¯ ºÎÀüÀÇ ÇϳªÀÌ°í ¿øÀÎÀÌ ½ÉÀå¿¡ ÀÖÀ» ¶§¸¦ ¸»ÇÑ´Ù. ±Þ¼º Á½ɺÎÀüÀº °íÇ÷¾Ð, ´ëµ¿¸ÆÆÇ ¹× ½Â¸ðÆÇ¸·Áõ, ½É±Ù¿°, Ư¹ß¼º ½É±ÙÁõ µî¿¡ À־ Á½ɽǿ¡ °©Àڱ⠻ý±ä ¼öÃà ºÎÀüÀ¸·Î ÀÎÇØ¼­ »ý±â´Â °ÍÀ̰í, Æó ¿ïÇ÷À» °¡Á®¿Í ¹ßÀÛ¼º È£Èí°ï¶õÀÌ »ý±ä´Ù. ±Þ¼º ¿ì½ÉºÎÀüÀº ±Þ¼º Æó»öÀü, ½É±Ù¿° µî¿¡ ÀÇÇØ ¿ì½ÉÀÇ ±Þ¼º ¼öÃà ºÎÀüÀÌ »ý°åÀ» ¶§¿¡ ÀÏÀ¸Å°°í ¿ì½ÉÀ¸·ÎÀÇ È¯·ù °¨¼Ò·Î ÀÎÇØ¼­ Ç÷¾ÐÀúÇÏ, ¼îÅ©°¡ »ý±ä´Ù. È£Èí°ï¶õ, ºóÈ£ÈíÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù.
  • backward heart failure
    ÈÄÇ⠽ɺÎÀü
  • bone marrow failure
    °ñ¼ö ±â´ÉºÎÁø
  • cardiac failure
    ½ÉºÎÀü, ½ÉºÎÀüÁõ
    µ¿ÀǾî=heart failure. ÃæºÐÇÑ Á¤¸Æ Ãæ¸¸¾ÐÀÌ Àִµ¥µµ »ýüÀÇ ¼ö¿ä¿¡ ´ëÇØ¼­ ÀûÀýÇÑ ¼øÈ¯À» À¯ÁöÇÒ ¼ö ¾ø°Ô µÈ »óÅÂ.
  • circulatory failure
    ¼øÈ¯ ºÎÀü
  • cohesional failure
    ÀÀÁý ÆÄ±«
    Á¢Âø·ÂÀÌ ÃæºÐÈ÷ Å©°í, Á¢ÂøÁ¦ Ãþ ¶Ç´Â ÇÇÂøÃ¼ ³»ºÎ¿¡ »ý±ä ÆÄ±«.
  • failure
    ºÎÀü, ºÎÀüÁõ, ÆÄ¼Õ
    ±â´ÉÀÇ ¼öÇàÀÌ ºÒ°¡´ÉÇÑ °Í.
  • fatigue failure
    ÇÇ·Î ÆÄ¼Õ
  • heart failure
    ½ÉºÎÀü
    ½É ¹ÚÃâ·®ÀÇ Àå¾Ö ¶Ç´Â Á¤¸Æ¾ÐÀÇ »ó½ÂÀ¸·Î ¹ß»ýÇϴ ƯÀ¯ÇÑ ÀÚ°¢Àû ¹× Ÿ°¢Àû Áõ»óÀ» Ư¡À¸·Î ÇÏ´Â ÀÓ»óÀû ÁõÈıº. ½É½Ç È®À强ÀÇ ¾Ð·Â Áõ´ë¿Í Àü½ÅÀÇ Çʿ䷮¿¡ ºÎÁ·ÇÑ ½É ¹ÚÃâ·®À» ¼ö¹ÝÇÏ´Â ½É±Ù ºÎÀü¿¡ ´ëÇÏ¿© °¡Àå ºó¹øÇÏ°Ô »ç¿ëµÇ´Â ¸»ÀÌ´Ù. Àü½Å Á¤¸Æ ¶Ç´Â Æó Á¤¸ÆÀÇ ¾î´À ÂÊÀÇ È®ÀåÀÌ ´õ¿í ½ÉÇѰ¡¿¡ µû¶ó ¿ìÃø ½ÉºÎÀü ȤÀº ÁÂÃø ½ÉºÎÀüÀ¸·Î ¼¼ºÐµÉ ¶§°¡ ¸¹´Ù.
  • hepatic failure
    °£ ±â´É ºÎÀü, °£ ºÎÀüÁõ, °£ ºÎÀü
    °£ÀÌ Á¦ ±â´ÉÀ» ¼öÇàÇÏÁö ¸øÇÏ´Â º´Àû »óÅÂ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
electroshock therapy A form of treatment of mental disorders in which convulsions are produced by the passage of an electric current through the brain.
Synonym: convulsive therapy, electroconvulsive therapy.
(05 Mar 2000)
electroshock Induction of a stress reaction in experimental subjects by means of an electrical shock; applies to either convulsive or non-convulsive states.
(12 Dec 1998)
radiotherapy dosage The total amount of radiation absorbed by tissues as a result of radiotherapy.
(12 Dec 1998)
gene dosage <molecular biology> Number of copies of a particular gene locus in the genome, in most cases either one or two.
(18 Nov 1997)
gene dosage compensation The putative mechanism that adjusts the X-linked phenotypes of males and females to compensate for the haploid state in males and the diploid state in females. It is now largely ascribed to lyonization which compensates the mean of the dose but not its variance, which is greater in females.
(05 Mar 2000)
gene dosage effect In codominant alleles, the more or less linear relationship between the phenotypic value and the number of genes of one type substituted by another type.
(05 Mar 2000)
dosage The determination and regulation of the size, frequency and number of doses.
(18 Nov 1997)
dosage compensation <genetics> A genetic regulatory mechanism which operates to equalise the phenotypic expression of characteristics determined by genes on the x chromosome so that they are equally expressed in the xy male and the xx female.
(12 Dec 1998)
dosage effect The alteration of a phenotype by an increased dosage, or amount, of the product of the gene.
(09 Oct 1997)
dosage forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. They include capsules, liniments, ointments, pharmaceutical solutions, powders, tablets, etc.
(12 Dec 1998)
dosage schedule A scheme set up to determine and regulate size, frequency and number of doses.
(18 Nov 1997)
acute kidney failure <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect).
Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
acute renal failure <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect).
Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
acute respiratory failure Loss of pulmonary function either acute or chronic that results in hypoxaemia or hypercarbia.
(05 Mar 2000)
backward heart failure A concept (formerly considered mutually exclusive of forward heart failure) that maintains that the phenomena of congestive heart failure result from passive engorgement of the veins caused by a "backward" rise in pressure proximal to the failing cardiac chambers.
Compare: forward heart failure.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • electroshock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©(Ãæ°Ý)¿ä¹ý
  • dosage
    Åõ¾à;Á¶Á¦;¾àÀÇ º¹¿ë·®(X¼±¹æ»ç µîÀÇ)ÀûÀÀ·®;Æ÷µµÁÖÀÇ Ç°Áú°³·®À» À§ÇÑ ´ç¹Ð;ºê·£µð µûÀ§ÀÇ Ã·°¡;ÁÖ¾îÁø ºÐ·®
  • electroshock
    Á¤½Åº´ÀÇ Àü°Ý ¿ä¹ý
  • maximum permissible dosage
    (¹æ»ç´É) ÃÖ´ë Çã¿ë Á¶»ç Àû·®
  • failure
    ½ÇÆÐ,°á
  • failure
    ½Ç¼ö;½ÇÆÐ;½ÇÆÐÀÚ;À߸øµÈ °Í;½ÇÆÐÇÑ °èȹ;Ÿ¸;ºÒÀÌÇà;ºÎÁ·;ºÒÃæºÐ;¾øÀ½;°¨Åð;¼èÅð;ÁöºÒÁ¤Áö;ÆÄ»ê;°íÀå;Á¤Áö;ÆÄ±«;ÆÄ¼Õ;³«Á¦
  • heart failure
    ½ÉÀ帶ºñ;½ÉÀå¹ßÀÛ
  • power failure
    Á¤Àü;Àü±â°íÀå
  • therapy
    Ä¡·á; ¿ä¹ý
  • Xray therapy
    ¿¢½º¼± ¿ä¹ý
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cellar therapy
    =CELL THERAPY
  • deep therapy
    ½ÉºÎ X¼± Ä¡·á(ÁÖ´ë»óÀº ¾Ç¼º Á¾¾ç)
  • electric shock therapy
    (Á¤ÀÇ)Àü±â ¼îÅ©¿ä¹ý
  • electroconvulsive therapy
    =ELECTROSHOCK THERAPY
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á